This study evaluates whether YM443 causes any changes in the electrocardiogram of healthy adults.
Each subject participates in all four treatment periods separated by washout periods. In order to maintain the blind between arms, all subjects will receive the same number of tablets per day in each period of either active drug or placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
QUADRUPLE
Enrollment
80
Unnamed facility
Tacoma, Washington, United States
Mean change in the QTcF (Fridericia's correction) between each active treatment and placebo
Time frame: Following four days of dosing
The mean change of the QTcI (Individual correction) and QTcB (Bazett's correction) between each active treatment and placebo.
Time frame: Following four days of dosing
The pharmacokinetics of YM443 in these subjects
Time frame: Day 5
The safety and tolerability of YM443
Time frame: Following four days of dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.